CN117045754A - Traditional Chinese medicine composition for treating fibrillation symptoms and preparation method and application thereof - Google Patents
Traditional Chinese medicine composition for treating fibrillation symptoms and preparation method and application thereof Download PDFInfo
- Publication number
- CN117045754A CN117045754A CN202311205581.8A CN202311205581A CN117045754A CN 117045754 A CN117045754 A CN 117045754A CN 202311205581 A CN202311205581 A CN 202311205581A CN 117045754 A CN117045754 A CN 117045754A
- Authority
- CN
- China
- Prior art keywords
- parts
- traditional chinese
- chinese medicine
- decoction
- root
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 99
- 239000000203 mixture Substances 0.000 title claims abstract description 26
- 206010061592 cardiac fibrillation Diseases 0.000 title claims abstract description 24
- 230000002600 fibrillogenic effect Effects 0.000 title claims abstract description 24
- 208000024891 symptom Diseases 0.000 title claims abstract description 24
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 208000011580 syndromic disease Diseases 0.000 claims abstract description 36
- 241000255789 Bombyx mori Species 0.000 claims abstract description 12
- 241000258920 Chilopoda Species 0.000 claims abstract description 11
- 241000361919 Metaphire sieboldi Species 0.000 claims abstract description 11
- 241001522129 Pinellia Species 0.000 claims abstract description 11
- 235000017166 Bambusa arundinacea Nutrition 0.000 claims abstract description 10
- 235000017491 Bambusa tulda Nutrition 0.000 claims abstract description 10
- 241000202726 Bupleurum Species 0.000 claims abstract description 10
- 244000183685 Citrus aurantium Species 0.000 claims abstract description 10
- 235000007716 Citrus aurantium Nutrition 0.000 claims abstract description 10
- 244000082204 Phyllostachys viridis Species 0.000 claims abstract description 10
- 235000015334 Phyllostachys viridis Nutrition 0.000 claims abstract description 10
- 239000011425 bamboo Substances 0.000 claims abstract description 10
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 9
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 9
- 235000017443 Hedysarum boreale Nutrition 0.000 claims abstract description 9
- 235000007858 Hedysarum occidentale Nutrition 0.000 claims abstract description 9
- 241000239226 Scorpiones Species 0.000 claims abstract description 9
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 claims abstract description 9
- 241000212322 Levisticum officinale Species 0.000 claims abstract description 8
- 239000001645 levisticum officinale Substances 0.000 claims abstract description 8
- 235000009467 Carica papaya Nutrition 0.000 claims abstract description 7
- 240000006432 Carica papaya Species 0.000 claims abstract description 7
- 244000236658 Paeonia lactiflora Species 0.000 claims abstract description 7
- 235000008598 Paeonia lactiflora Nutrition 0.000 claims abstract description 7
- 240000004534 Scutellaria baicalensis Species 0.000 claims abstract description 6
- 235000017089 Scutellaria baicalensis Nutrition 0.000 claims abstract description 6
- 240000007164 Salvia officinalis Species 0.000 claims abstract description 5
- 235000005412 red sage Nutrition 0.000 claims abstract description 5
- 238000011282 treatment Methods 0.000 claims description 49
- 238000002156 mixing Methods 0.000 claims description 29
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 28
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 18
- 239000000843 powder Substances 0.000 claims description 15
- 239000002994 raw material Substances 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 12
- 238000001914 filtration Methods 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 6
- 238000002791 soaking Methods 0.000 claims description 6
- 238000005303 weighing Methods 0.000 claims description 6
- 239000003826 tablet Substances 0.000 claims description 5
- 241000207929 Scutellaria Species 0.000 claims description 4
- 239000011248 coating agent Substances 0.000 claims description 4
- 238000000576 coating method Methods 0.000 claims description 4
- WTPPRJKFRFIQKT-UHFFFAOYSA-N 1,6-dimethyl-8,9-dihydronaphtho[1,2-g][1]benzofuran-10,11-dione;1-methyl-6-methylidene-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-10,11-dione Chemical compound O=C1C(=O)C2=C3CCCC(=C)C3=CC=C2C2=C1C(C)=CO2.O=C1C(=O)C2=C3CCC=C(C)C3=CC=C2C2=C1C(C)=CO2 WTPPRJKFRFIQKT-UHFFFAOYSA-N 0.000 claims description 3
- 240000000425 Chaenomeles speciosa Species 0.000 claims description 3
- 235000006484 Paeonia officinalis Nutrition 0.000 claims description 3
- 235000013399 edible fruits Nutrition 0.000 claims description 3
- 239000006072 paste Substances 0.000 claims description 3
- 244000132619 red sage Species 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 244000170916 Paeonia officinalis Species 0.000 claims 1
- 206010044565 Tremor Diseases 0.000 abstract description 55
- 230000000694 effects Effects 0.000 abstract description 23
- 210000004369 blood Anatomy 0.000 abstract description 22
- 239000008280 blood Substances 0.000 abstract description 22
- 206010062717 Increased upper airway secretion Diseases 0.000 abstract description 21
- 208000026435 phlegm Diseases 0.000 abstract description 21
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 2
- 201000006517 essential tremor Diseases 0.000 description 20
- 201000010099 disease Diseases 0.000 description 13
- 229940079593 drug Drugs 0.000 description 11
- 230000002829 reductive effect Effects 0.000 description 11
- 210000004185 liver Anatomy 0.000 description 10
- 210000003414 extremity Anatomy 0.000 description 9
- 238000003745 diagnosis Methods 0.000 description 7
- 210000000952 spleen Anatomy 0.000 description 7
- 238000012360 testing method Methods 0.000 description 6
- 208000005392 Spasm Diseases 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 5
- 210000002435 tendon Anatomy 0.000 description 5
- 206010014080 Ecchymosis Diseases 0.000 description 4
- 230000010354 integration Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- MEAPRSDUXBHXGD-UHFFFAOYSA-N 3-chloro-n-(4-propan-2-ylphenyl)propanamide Chemical compound CC(C)C1=CC=C(NC(=O)CCCl)C=C1 MEAPRSDUXBHXGD-UHFFFAOYSA-N 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 3
- 208000012661 Dyskinesia Diseases 0.000 description 3
- 208000032023 Signs and Symptoms Diseases 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 238000001467 acupuncture Methods 0.000 description 3
- 230000006838 adverse reaction Effects 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 229960004604 propranolol hydrochloride Drugs 0.000 description 3
- 210000003296 saliva Anatomy 0.000 description 3
- 235000006264 Asimina triloba Nutrition 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 2
- 241000112528 Ligusticum striatum Species 0.000 description 2
- 241001481692 Mesobuthus martensii Species 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 241001106477 Paeoniaceae Species 0.000 description 2
- 208000022531 anorexia Diseases 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 230000001914 calming effect Effects 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 208000014951 hematologic disease Diseases 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 210000001364 upper extremity Anatomy 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010003671 Atrioventricular Block Diseases 0.000 description 1
- 108030001720 Bontoxilysin Proteins 0.000 description 1
- 241000252505 Characidae Species 0.000 description 1
- 206010008469 Chest discomfort Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 208000014094 Dystonic disease Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010064950 Head titubation Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 235000003332 Ilex aquifolium Nutrition 0.000 description 1
- 235000002296 Ilex sandwicensis Nutrition 0.000 description 1
- 235000002294 Ilex volkensiana Nutrition 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 206010073211 Postural tremor Diseases 0.000 description 1
- 206010072377 Psychogenic tremor Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 206010040007 Sense of oppression Diseases 0.000 description 1
- 241000244155 Taenia Species 0.000 description 1
- 208000003217 Tetany Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 108010057266 Type A Botulinum Toxins Proteins 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 229940053031 botulinum toxin Drugs 0.000 description 1
- 229940094657 botulinum toxin type a Drugs 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 206010007625 cardiogenic shock Diseases 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000009514 concussion Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 208000010118 dystonia Diseases 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 238000010832 independent-sample T-test Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000015263 low fat diet Nutrition 0.000 description 1
- 235000014659 low sodium diet Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000008897 memory decline Effects 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- 239000003087 receptor blocking agent Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000001020 rhythmical effect Effects 0.000 description 1
- 208000037974 severe injury Diseases 0.000 description 1
- 230000009528 severe injury Effects 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000020685 sleep-wake disease Diseases 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000004206 stomach function Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000001103 thalamus Anatomy 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/62—Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/646—Arachnids, e.g. spiders, scorpions, ticks or mites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/648—Myriapods, e.g. centipedes or millipedes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/233—Bupleurum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/732—Chaenomeles, e.g. flowering quince
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
- A61K36/8888—Pinellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Insects & Arthropods (AREA)
- Tropical Medicine & Parasitology (AREA)
- Animal Husbandry (AREA)
- Neurosurgery (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a traditional Chinese medicine composition for treating fibrillation syndromes, a preparation method and application thereof, belonging to the technical field of traditional Chinese medicines, wherein the traditional Chinese medicine composition comprises the following components in parts by weight: 10-20 parts of dried orange peel, 5-15 parts of pinellia tuber, 5-15 parts of bamboo shavings, 5-15 parts of bitter orange, 5-15 parts of bupleurum, 15-25 parts of white peony root, 5-15 parts of baikal skullcap root, 5-15 parts of honey-fried licorice root, 10-20 parts of red sage root, 10-20 parts of szechuan lovage rhizome, 20-30 parts of papaya, 2-6 parts of scorpion, 1-4 parts of centipede, 5-15 parts of earthworm and 2-10 parts of stiff silkworm. The invention has good effect on treating phlegm turbidity and blood stasis type tremor syndrome, can obviously improve limb tremor symptoms, daily life capacity and clinical symptoms of a tremor patient, has the total tremor curative effect up to 82.5%, and has the total traditional Chinese medicine syndrome medical curative effect up to 70%.
Description
Technical Field
The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for treating a fibrillation syndrome, and a preparation method and application thereof.
Background
The tremor syndrome refers to the traditional Chinese medical condition with shaking of the head or limbs and tremor as the main clinical manifestation, the light person only has shaking of the head or tremor of the hands and feet, the heavy person has shaking of the head, the tremor of the limbs cannot stop, the tremor of the limbs occurs frequently in middle-aged and elderly people, the onset of the disease is delayed, the disease is gradually aggravated, and the family genetic medical history often exists. The clinical symptoms of the tremor syndrome are recorded in the first part of the Huangdi's internal channel, all of which are liver-qi, and the first part of the Jinkui's Mian Jib-Shi-Jib disease and pulse syndrome treatment, namely, rou Jib … … head shaking, vomiting, tetany and even angular bows and back.
The traditional Chinese medicine considers that the disease of the tremor is located in the tendons and vessels, closely related to the liver and spleen, and the etiology of the disease is related to depression, anger and diet loss. Patients with tremor symptoms often have sensitive emotion, are easy to anxiety and tension, have unsmooth liver qi stagnation, slow and astringent blood circulation, and spontaneous tremors, and are just like Ming Zhang Yuan Zhengyue holly Zheng Feng (Ming Zheng Yue Shu): the liver is the eastern viscera, stores blood, and is the most common wind, liver diseases are caused by blood diseases and tendons are malnourished, and tendons are all the more common, such as dizziness and rigidity, and belongs to the syndrome of wind. Patients with tremor often take paste with thick taste or have addiction to alcohol, which can hurt spleen and obstruct stomach, promote internal heat, phlegm and saliva to be abundant, flow channels and collaterals, disturb tendons and vessels and generate wind. The Qing dynasty physician He Mengyao describes in medical practice, tremor: the excessive wind-wood causes the spleen-soil deficiency, the spleen is the root of the four limbs, and the four limbs are the end of the spleen, so the disease is called wind-dampness end disease; excessive wind-fire and spleen deficiency can not move its body fluids, and phlegm-dampness also stops gathering and also removes phlegm. In conclusion, emotional loss of the liver and improper diet can obstruct the spleen, turbid phlegm and blood stasis can block the channels and collaterals, so that the tendons and collaterals are not nourished, tremor wind-induced generation is the root cause of the disease, and the treatment is based on the fundamental treatment of resolving phlegm, removing blood stasis, calming endogenous wind and relieving spasm. The traditional Chinese medicine treatment of the modern fibrillation syndrome is mainly based on acupuncture treatment and auxiliary traditional Chinese medicine decoction is matched, the acupuncture treatment is limited by the fact that the acupuncture techniques of doctors are difficult to unify, the patient is frequently in treatment, the treatment course is long, and further popularization and research cannot be carried out, so that the compound traditional Chinese medicine capable of treating the fibrillation syndrome in a standardized mode and easy to clinically apply is developed.
In modern medicine, according to the tremor of the head and the upper limbs of the patient with tremor, the frequency is 4-12 Hz, no dystonia exists, 50% of the patients have family history and other characteristics, and the patients are classified into Essential Tremor (ET) which is a dyskinesia disease of the nervous system. Epidemiological studies have shown that the prevalence of ET is about 0.9% worldwide, 6.0% for men over 55 years of age in our country, 3.6% for women, and significantly increased with age. ET is the most common dyskinesia disease at present, and researches show that long-term disease of ET can be secondary to various diseases such as sleep disorder, memory decline, dementia, depression, parkinson disease and the like. With the deepening of population aging, the number of ET patients in China is increased year by year, and the ET not only affects the life quality of the patients, but also brings economic pressure to society.
The pathogenesis of ET is not clear, and the most widely accepted pathological mechanism in the prior studies is the abnormal rhythmic concussion of the cerebral cortex, cerebellum, thalamus and brainstem of the motor area with the gradual increase of age, which often leads to the occurrence of ET. Western medicine for ET is in bottleneck period, single medicine use and great side effect, mainly including oral beta 2 receptor blocker (such as propranolol, alolol) and injection type A botulinum toxin. Beta 2 receptor blockers exert therapeutic effects to reduce tremor frequency and amplitude by inhibiting peripheral beta 2 receptors, but often cause adverse reactions such as heart rate slowing, blood pressure lowering and the like, while botulinum toxin type a injections exert therapeutic effects by blocking the release of acetylcholine, which only improve tremor amplitude, do not significantly improve tremor frequency, and can cause localized muscle weakness, so that the current western medicine is a pair of sword-knives for the treatment of ET.
Along with the vigorous development of traditional Chinese medicine industry, traditional Chinese medicine has the advantages of being small in side effect, durable in drug effect, high in patient compliance, capable of playing roles from a plurality of ion channels and multiple targets and the like in the treatment of a plurality of diseases, and can obviously improve clinical symptoms and prognosis of patients. Therefore, if a traditional Chinese medicine capable of effectively preventing and treating the fibrillation syndromes can be researched and developed, the traditional Chinese medicine has important significance for clinical treatment of the fibrillation syndromes.
Disclosure of Invention
In order to solve the technical problems, the invention provides a traditional Chinese medicine composition for treating the fibrillation syndromes, a preparation method and application thereof, and the traditional Chinese medicine composition has a good effect on treating the phlegm turbidity and blood stasis type fibrillation syndromes.
The invention provides a traditional Chinese medicine pathogenesis of fibrillation syndrome, which is that: stagnation of turbid phlegm and blood stasis, and spontaneous tremor of endogenous wind. Clinical manifestations of phlegm turbidity and blood stasis type tremor syndrome are characterized by: main evidence: tremor and shaking of the head and limbs cannot be stopped by oneself; secondary syndrome: chest fullness and oppression, nausea and anorexia, bitter taste and sticky mouth, limb heaviness, dysphoria and irritability, and purple lips and nails; tongue appearance: dark purple tongue with ecchymosis and ecchymosis, yellow and greasy tongue coating; pulse condition: the pulse is wiry and slippery.
Based on the pathogenesis analysis, the invention provides the following scheme:
the invention provides a traditional Chinese medicine composition for treating fibrillation symptoms, which comprises the following components in parts by weight:
10-20 parts of dried orange peel, 5-15 parts of pinellia tuber, 5-15 parts of bamboo shavings, 5-15 parts of bitter orange, 5-15 parts of bupleurum, 15-25 parts of white peony root, 5-15 parts of baikal skullcap root, 5-15 parts of honey-fried licorice root, 10-20 parts of red sage root, 10-20 parts of szechuan lovage rhizome, 20-30 parts of papaya, 2-6 parts of scorpion, 1-4 parts of centipede, 5-15 parts of earthworm and 2-10 parts of stiff silkworm.
Preferably, the composition comprises the following components in parts by weight: 15 parts of dried orange peel, 10 parts of pinellia tuber, 10 parts of bamboo shavings, 10 parts of bitter orange, 10 parts of bupleurum, 20 parts of white paeony root, 10 parts of baical skullcap root, 10 parts of honey-fried licorice root, 15 parts of danshen root, 15 parts of szechuan lovage rhizome, 25 parts of common floweringquince fruit, 3 parts of scorpion, 2 parts of centipede, 10 parts of earthworm and 5 parts of stiff silkworm.
The invention also provides a preparation method of the traditional Chinese medicine composition for treating the fibrillation syndromes, which comprises the following steps:
weighing and mixing the raw materials according to the weight parts, and crushing to obtain mixed traditional Chinese medicine powder;
the mixed traditional Chinese medicine powder and water are mixed according to the mass ratio of 1: (10-20), soaking for 30-40 min, and decocting with strong fire for the first time to obtain first decoction and medicinal residues;
mixing the residues with water, and decocting with slow fire for the second time to obtain a second decoction and a second residue;
mixing the secondary medicinal residues with water, and decocting with slow fire for the third time to obtain a third decoction and a third medicinal residue;
mixing the first decoction, the second decoction and the third decoction, filtering, and concentrating in 100deg.C water bath to 1/3 of the original volume.
Preferably, the first time of the strong fire decoction is 60-70 min.
Preferably, the mixing mass ratio of the dregs to the water is 1: (8-12), and the time of the second slow fire decoction is 40-50 min.
Preferably, the mixing mass ratio of the secondary medicine residues to the water is 1: (3-7), wherein the time of the third slow fire decoction is 20-30 min.
The invention also provides application of the traditional Chinese medicine composition in preparation of medicines for treating the fibrillation syndromes.
The invention also provides a medicament for treating the fibrillation symptoms, and the raw materials comprise the Chinese medicinal composition.
Preferably, the medicament further comprises pharmaceutically acceptable auxiliary materials.
Preferably, the dosage form of the medicament comprises powder, pill, granule, paste or tablet.
Compared with the prior art, the invention has the following advantages and technical effects:
the traditional Chinese medicine composition is prepared according to the principle of monarch, minister, assistant and guide, and takes dried orange peel, pinellia tuber, bamboo shavings, bitter orange, scorpion, centipede, stiff silkworm and earthworm as monarch drugs to clear heat, resolve phlegm, remove blood stasis and dredge collaterals; wherein the pinellia tuber and the dried orange peel warm dryness and promote qi circulation, dispel dampness and resolve phlegm; caulis Bambusae in Taenia and fructus Aurantii have effects of clearing heat, regulating stomach function, lowering adverse qi and removing stagnation; the four medicines are combined into a 'warm biliary soup' to ensure that the biliary qi is not dry at normal temperature, and phlegm heat is excessive and pathogenic factors are relieved. The scorpion has the functions of stopping wind and relieving spasm, centipede has the functions of softening hardness and dissipating stagnation, and the two medicines are mutually combined to form the medicine "stopping spasm and dissipating stasis" for expelling and dredging collaterals and stopping wind and stopping convulsion. The stiff silkworm is used for dispelling wind and dredging collaterals, and the earthworm is used for promoting blood circulation and removing blood stasis, and the two medicine phases are combined into the stiff silkworm powder for dispelling wind and relieving spasm, and removing blood stasis and resolving masses. Bupleurum, white peony root and baical skullcap root are taken as ministerial drugs, so as to sooth liver, relieve depression, soften liver, nourish yin, raise liver and prevent dryness and heat; the red sage root, the szechuan lovage rhizome and the papaya are used as adjuvants to remove blood stasis and promote tissue regeneration, so that the blood circulation is improved; radix Glycyrrhizae Preparata is used as the guiding drug to regulate the property of the drugs, and is sweet and neutral in nature to prevent severe injury to spleen and stomach. The Chinese medicinal materials are combined to play roles in resolving phlegm, removing blood stasis, calming endogenous wind and relieving spasm. The traditional Chinese medicine composition has good treatment effect on the phlegm turbidity and blood stasis type tremor, can obviously improve limb tremor symptoms, daily life capacity and clinical symptoms of a patient suffering from the tremor, has the total tremor curative effect of 82.5%, and has the total traditional Chinese medicine syndrome curative effect of 70%. The traditional Chinese medicine composition disclosed by the invention is used for treating the fibrillation symptoms, and has no obvious toxic or side effect and adverse reaction.
Compared with western medicine treatment, the traditional Chinese medicine composition for treating the fibrillation syndromes obviously improves clinical symptoms of patients, reduces economic burden and national medical cost of the patients, widens the possibility of the current fibrillation syndromes treatment while solving clinical problems, further promotes the vigorous development of the traditional Chinese medicine treatment, and has great social value.
Detailed Description
Various exemplary embodiments of the invention will now be described in detail, which should not be considered as limiting the invention, but rather as more detailed descriptions of certain aspects, features and embodiments of the invention.
It is to be understood that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention. In addition, for numerical ranges in this disclosure, it is understood that each intermediate value between the upper and lower limits of the ranges is also specifically disclosed. Every smaller range between any stated value or stated range, and any other stated value or intermediate value within the stated range, is also encompassed within the invention. The upper and lower limits of these smaller ranges may independently be included or excluded in the range.
Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although only preferred methods and materials are described herein, any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention. All documents mentioned in this specification are incorporated by reference for the purpose of disclosing and describing the methods and/or materials associated with the documents. In case of conflict with any incorporated document, the present specification will control.
It will be apparent to those skilled in the art that various modifications and variations can be made in the specific embodiments of the invention described herein without departing from the scope or spirit of the invention. Other embodiments will be apparent to those skilled in the art from consideration of the specification of the present invention. The specification and examples of the present invention are exemplary only.
As used herein, the terms "comprising," "including," "having," "containing," and the like are intended to be inclusive and mean an inclusion, but not limited to.
The "parts" in the present invention are all parts by mass unless otherwise specified.
Example 1
The traditional Chinese medicine composition for preventing and treating phlegm turbidity and blood stasis type tremor is prepared from the following raw materials:
15g of dried orange peel, 10g of pinellia tuber, 10g of bamboo shavings, 10g of bitter orange, 10g of bupleurum, 20g of white peony root, 10g of baikal skullcap root, 10g of honey-fried licorice root, 15g of root of red rooted saliva, 15g of Ligusticum wallichii, 25g of pawpaw, 3g of buthus martensi karsch, 2g of centipede, 10g of earthworm and 5g of stiff silkworm.
The preparation method comprises the following steps:
weighing and mixing the raw materials according to the weight parts, and crushing to obtain mixed traditional Chinese medicine powder; mixing traditional Chinese medicine powder with water according to a mass ratio of 1:15, soaking for 40min, and decocting with strong fire for 70min to obtain first decoction and residue; the mass ratio of the dregs to the water is 1:10, decocting with slow fire for 50min to obtain second decoction and second residue; the mass ratio of the secondary medicine residues to the water is 1:5, mixing, and decocting with slow fire for 30min for the third time to obtain a third decoction and a third medicinal residue; mixing the first decoction, the second decoction and the third decoction, filtering, and concentrating in 100deg.C water bath to 1/3 of the original volume.
Example 2
The traditional Chinese medicine composition for preventing and treating phlegm turbidity and blood stasis type tremor is prepared from the following raw materials:
10g of dried orange peel, 5g of pinellia tuber, 5g of bamboo shavings, 5g of bitter orange, 5g of bupleurum, 15g of white peony root, 5g of baikal skullcap root, 5g of honey-fried licorice root, 10g of red sage root, 10g of szechuan lovage rhizome, 20g of papaya, 2g of scorpion, 1g of centipede, 5g of earthworm and 2g of stiff silkworm.
The preparation method comprises the following steps:
weighing and mixing the raw materials according to the weight parts, and crushing to obtain mixed traditional Chinese medicine powder; mixing traditional Chinese medicine powder with water according to a mass ratio of 1:10, soaking for 30min, and decocting with strong fire for 60min to obtain first decoction and residue; the mass ratio of the dregs to the water is 1:8, mixing, and decocting with slow fire for 40min to obtain a second decoction and a second residue; the mass ratio of the secondary medicine residues to the water is 1:3 mixing, decocting with slow fire for 20min to obtain the third decoction and the third residue; mixing the first decoction, the second decoction and the third decoction, filtering, and concentrating in 100deg.C water bath to 1/3 of the original volume.
Example 3
The traditional Chinese medicine composition for preventing and treating phlegm turbidity and blood stasis type tremor is prepared from the following raw materials:
20g of dried orange peel, 15g of pinellia tuber, 15g of bamboo shavings, 15g of bitter orange, 15g of bupleurum, 25g of white peony root, 15g of baikal skullcap root, 15g of honey-fried licorice root, 20g of root of red rooted saliva, 20g of Ligusticum wallichii, 30g of pawpaw, 6g of buthus martensi karsch, 4g of centipede, 15g of earthworm and 10g of stiff silkworm.
The preparation method comprises the following steps:
weighing and mixing the raw materials according to the weight parts, and crushing to obtain mixed traditional Chinese medicine powder; mixing traditional Chinese medicine powder with water according to a mass ratio of 1:20, soaking for 35min, and decocting with strong fire for 65min to obtain first decoction and residue; the mass ratio of the dregs to the water is 1:12, decocting with slow fire for 45min to obtain second decoction and second residue; the mass ratio of the secondary medicine residues to the water is 1:7, mixing, and decocting with slow fire for 25min to obtain a third decoction and a third residue; mixing the first decoction, the second decoction and the third decoction, filtering, and concentrating in 100deg.C water bath to 1/3 of the original volume.
Comparative example 1
The difference from example 1 is that the raw materials do not include stiff silkworm and earthworm.
The traditional Chinese medicine composition for preventing and treating phlegm turbidity and blood stasis type tremor is prepared from the following raw materials:
15g of dried orange peel, 10g of pinellia tuber, 10g of bamboo shavings, 10g of bitter orange, 10g of bupleurum, 20g of white paeony root, 10g of baical skullcap root, 10g of honey-fried licorice root, 15g of danshen root, 15g of szechuan lovage rhizome, 25g of common floweringquince fruit, 3g of scorpion and 2g of centipede.
The preparation method comprises the following steps:
weighing and mixing the raw materials according to the weight parts, and crushing to obtain mixed traditional Chinese medicine powder; mixing traditional Chinese medicine powder with water according to a mass ratio of 1:15, soaking for 40min, and decocting with strong fire for 70min to obtain first decoction and residue; the mass ratio of the dregs to the water is 1:10, decocting with slow fire for 50min to obtain second decoction and second residue; the mass ratio of the secondary medicine residues to the water is 1:5, mixing, and decocting with slow fire for 30min for the third time to obtain a third decoction and a third medicinal residue; mixing the first decoction, the second decoction and the third decoction, filtering, and concentrating in 100deg.C water bath to 1/3 of the original volume.
Experimental example 1
1. Clinical verification
1.1 general data
The study subjects select 120 cases of patients with clear diagnosis of phlegm turbidity and blood stasis type fibrillation symptoms from the clinic of the affiliated hospital of Liaoning traditional Chinese medicine university in 2016-2022 with the age range of 40-85 years.
1.2 diagnostic criteria
Western diagnostic criteria: reference is made to 2009 to Essential Tremor (ET) diagnostic criteria of the united states dyskinesia association and the world tremor research organization:
core diagnostic criteria: bilateral forearm and upper limb sustained and apparent actionable and/or postural tremor, or head tremor alone, but without muscular tension disorder, without other neurological signs.
Support diagnostic criteria: (1) course of disease for 3 years or more; (2) a positive family history; (3) the tremor symptom can be relieved after drinking.
Diagnostic criteria for traditional Chinese medicine: reference is made to the diagnosis standard of "Hurricane syndrome" in traditional Chinese medicine science published by Chinese traditional medicine publishing company in 2017; the diagnosis standard of turbid phlegm and blood stasis refers to the "traditional Chinese medicine clinical diagnosis and treatment terminology syndrome part", 2002 edition "guidelines for clinical research of traditional Chinese medicine (new medicine)": main evidence: tremor of limbs and/or head, shake cannot be stopped by oneself;
secondary syndrome: bitter and sticky mouth, limb heaviness, nausea, anorexia, and bluish purple lips and nails;
tongue appearance: dark purple tongue with ecchymosis and ecchymosis, yellow and greasy tongue coating;
pulse condition: the pulse is wiry and slippery; (the main syndrome should be satisfied and 3 or more secondary syndromes should be combined with tongue pulse for joint diagnosis).
1.3 inclusion criteria:
(1) Meets the diagnosis standard of phlegm turbidity and blood stasis type tremor syndrome (essential tremor).
(2) The age is between 40 and 85 years, and the sex is unlimited.
(3) Is willing to participate in the clinical observation and the drug treatment.
1.4 exclusion criteria:
(1) Not simultaneously accords with the diagnosis standard of Chinese and Western medicine and the diagnosis standard of Chinese medicine symptoms;
(2) Cases with severe center of gravity, liver, kidney and hematopoietic system diseases and unstable conditions to be treated; cases with psychotic disorders;
(3) A history of neurological trauma or psychogenic tremors with clinical diagnostic evidence within 3 months prior to onset;
(4) Heart rate less than 60 beats/min, or cases with hypotension, atrioventricular block, and bronchial asthma;
(5) Allergic to the known ingredients of the drugs.
1.5 case drop, reject criteria
(1) The patient asks for withdrawal by himself or fails to adhere to the case of the end of the course of treatment;
(2) Incomplete case entry data affects the validity judgment;
(3) Patient compliance is poor and medication is not taken at prescribed doses and frequently or is taking medications that interfere with observations.
1.6 stop criteria
(1) Abnormal safety indexes occur in the test process, and the illness state is aggravated acutely and needs to be stopped immediately;
(2) Adverse reactions such as cardiogenic shock, serious arrhythmia and the like occur in the test process and need to be stopped immediately;
(3) The occurrence of specific physiological conditions or accidents during the test procedure leads to discontinuation of the treatment.
120 patients enrolled according to the above criteria were randomized into A, B, C total of 3 groups of 40. The general data for three groups of patients were comparable (P > 0.05).
1.7 treatment regimen
Group A: propranolol hydrochloride tablet, 10mg, is taken orally three times a day, 8 weeks is a treatment course.
Group B: the Chinese medicinal decoction prepared in example 1 was orally taken at an amount of 100 mL/time, 3 times a day, 30 minutes after meals, 8 weeks as a treatment course.
Group C: the Chinese medicinal decoction prepared in comparative example 1 is orally taken with the dosage of 100 mL/time, 3 times a day, in the middle and late, 30 minutes after meals, and 8 weeks as a treatment course.
During the treatment period, the blood pressure and heart rate are monitored, the low-salt and low-fat diet is adopted, the consumption of strong wine, coffee, strong tea and other stimulating beverages is avoided, the consumption of spicy, greasy and uncooked foods is avoided, the strenuous exercise is avoided, and the patients with other basic diseases continue to take the conventional western medicine treatment.
1.8 Observation index
(1) Tetra essential tremor assessment scale;
(2) Bain-Findley tremor daily life ability assessment scale;
(3) Integral scale of Chinese medicine symptoms.
1.9 determination of efficacy
1.9.1 tremor degree curative effect evaluation standard
(1) The effect is shown: the integral of essential tremor of tetra s of the patient is reduced by more than or equal to 70%;
(2) the method is effective: patient's essential tremor score is reduced by greater than or equal to 30% and less than 70% earlier;
(3) invalidation: patient tetra essential tremor score was reduced by less than 30% earlier.
1.9.2 evaluation criterion for curative effect of traditional Chinese medicine syndrome
Reference to 2002 edition of guidelines for clinical study of New Chinese medicine, see Table 1 in particular:
table 1 evaluation criteria for the therapeutic efficacy of traditional Chinese medicine syndrome
| Has obvious effect | The clinical symptoms and signs are obviously improved, and the integral of symptoms is reduced by more than or equal to 70 percent. |
| Effective and effective | The clinical symptoms and signs are all improved, and the integral of symptoms is reduced by 30-70%. |
| Invalidation of | The clinical symptoms and signs are not obviously improved or even aggravated, and the integral of the syndrome is reduced<30％ |
1.10 evaluation of safety
After the 8-week course of treatment is over, the liver and kidney functions of the patient are detected, and the blood, urine and feces are normal.
1.11 statistical methods
Data were analyzed using SPSS 26.0 statistical software. The "average ± standard deviation" for measuring data "Indicating, paired t-test for intra-group pre-and post-treatment comparisons, and independent sample t-test for inter-group pre-and post-treatment comparisons; rank sum test is used for comparing the rank data; the counting data is checked by using chi-square, P<0.05 is statistically different by P<0.01 is a significant difference.
1.12 results
1.12.1 comparison of the score of essential tremor of TETRAS before and after treatment
The differences in the integration of tremor of the tetra s essential before treatment were statistically not significant (P > 0.05) and were comparable. The total tremor integral of the three groups after treatment is reduced (P < 0.05) compared with that before treatment, and the total tremor integral of the group B is obviously reduced (P < 0.05) compared with that of the group A, and the comparison results of the total tremor integral of the tetra s before and after treatment are shown in table 2:
table 2 comparison of the integration of post-treatment tetra essential tremor
1.12.2 comparative therapeutic effects on tremor degree
The obvious efficiency of the group A, namely the propranolol hydrochloride tablet treatment group is 12.50 percent, and the total effective rate is 60.00 percent (25/40); the group B adopts the traditional Chinese medicine of the example 1 for treatment, the obvious efficiency is 25.00 percent, and the total effective rate is 82.50 percent (33/40); through rank sum test, the difference of the curative effect of the tremor degree of each group has statistical significance (P < 0.05), and the comparison result of the curative effect of the tremor degree of each group is shown in Table 3:
table 3 comparative efficacy of tremor degree of each group
| Group of | Example number (n) | Has obvious effect | Effective and effective | Invalidation of | Total effective rate (%) |
| Group A | 40 cases | 5(12.50％) | 20(50.00％) | 15(37.50％) | 62.50 |
| Group B | 40 cases | 10(25.00％) | 23(57.50％) | 7(17.50％) | 82.50 |
| Group C | 40 cases | 7(17.50％) | 24(60.00％) | 9(22.5％) | 77.50 |
1.12.3 Integrated comparison of the daily Capacity of Bain-Findley tremor before and after treatment
The difference of the integration of the daily life capacities of the three groups of Bain-Findley tremors before treatment is not statistically significant (P is more than 0.05), and the three groups of Bain-Findley tremors are comparable. The daily life capacity integral of the three groups of Bain-Findley tremors after treatment is reduced (P is less than 0.05) compared with that before treatment, and the daily life capacity integral of the group B is obviously reduced (P is less than 0.05) compared with that of the group A of Bain-Findley tremors, and the comparison result of the daily life capacity integral of the Bain-Findley tremors before and after treatment of each group is shown in table 4:
TABLE 4 integration of daily life capacities of Bain-Findley tremor before and after treatment of each group
1.12.4 integral comparison of syndrome of Chinese medicine
The integral difference of the three groups of traditional Chinese medicine symptoms before treatment has no statistical significance (P is more than 0.05), and has comparability. The primary and secondary symptoms score of the three groups after treatment were reduced (P < 0.05) and the improvement of the traditional Chinese medicine symptoms was more remarkable (P < 0.05) than that of group a, and the results of the comparison of the primary symptom scores before and after treatment are shown in table 5:
table 5 comparison of scores of TCM syndromes before and after treatment of each group
Note that: comparison with the group before treatment * P＜0.05， ** P is less than 0.01; comparison with group A # P＜0.05， ## P＜0.01。
1.12.5 comparison of the curative effects of the traditional Chinese medical science
The obvious efficiency of the group A, namely the propranolol hydrochloride tablet treatment group is 12.50 percent, and the total effective rate is 60.00 percent (25/40); the group B adopts the traditional Chinese medicine of the example 1 for treatment, the obvious efficiency is 25.00 percent, and the total effective rate is 82.50 percent (33/40); through rank sum test, the difference of the curative effect of the tremor degree of each group has statistical significance (P < 0.05), and the comparison result of the curative effect of the tremor degree of each group is shown in Table 6:
comparative efficacy of the TCM syndromes of Table 6
| Group of | Example number (n) | Has obvious effect | Effective and effective | Invalidation of | Total effective rate (%) |
| Group A | 40 cases | 3(7.50％) | 20(50.00％) | 17(42.50％) | 57.50 |
| Group B | 40 cases | 7(17.50％) | 21(52.50％) | 12(30.00％) | 70.00 |
| Group C | 40 cases | 5(12.50％) | 20(50.00％) | 15(37.50％) | 62.50 |
1.12.6 safety evaluation
Patients in each group have no adverse reaction in 8 weeks of taking the medicine, and have normal blood, urine and stool and abnormal liver and kidney functions.
The above embodiments are only illustrative of the preferred embodiments of the present invention and are not intended to limit the scope of the present invention, and various modifications and improvements made by those skilled in the art to the technical solutions of the present invention should fall within the protection scope defined by the claims of the present invention without departing from the design spirit of the present invention.
Claims (10)
1. A traditional Chinese medicine composition for treating fibrillation syndrome is characterized in that: the coating comprises the following components in parts by weight:
10-20 parts of dried orange peel, 5-15 parts of pinellia tuber, 5-15 parts of bamboo shavings, 5-15 parts of bitter orange, 5-15 parts of bupleurum, 15-25 parts of white peony root, 5-15 parts of baikal skullcap root, 5-15 parts of honey-fried licorice root, 10-20 parts of red sage root, 10-20 parts of szechuan lovage rhizome, 20-30 parts of papaya, 2-6 parts of scorpion, 1-4 parts of centipede, 5-15 parts of earthworm and 2-10 parts of stiff silkworm.
2. The traditional Chinese medicine composition for treating the fibrillation symptoms according to claim 1, wherein the traditional Chinese medicine composition is characterized in that: the coating comprises the following components in parts by weight: 15 parts of dried orange peel, 10 parts of pinellia tuber, 10 parts of bamboo shavings, 10 parts of bitter orange, 10 parts of bupleurum, 20 parts of white paeony root, 10 parts of baical skullcap root, 10 parts of honey-fried licorice root, 15 parts of danshen root, 15 parts of szechuan lovage rhizome, 25 parts of common floweringquince fruit, 3 parts of scorpion, 2 parts of centipede, 10 parts of earthworm and 5 parts of stiff silkworm.
3. A method for preparing a traditional Chinese medicine composition for treating a fibrillation syndrome as claimed in claim 1 or 2, characterized in that: the method comprises the following steps:
weighing and mixing the raw materials according to the weight parts, and crushing to obtain mixed traditional Chinese medicine powder;
the mixed traditional Chinese medicine powder and water are mixed according to the mass ratio of 1: (10-20), soaking for 30-40 min, and decocting with strong fire for the first time to obtain first decoction and medicinal residues;
mixing the residues with water, and decocting with slow fire for the second time to obtain a second decoction and a second residue;
mixing the secondary medicinal residues with water, and decocting with slow fire for the third time to obtain a third decoction and a third medicinal residue;
mixing the first decoction, the second decoction and the third decoction, filtering, and concentrating in 100deg.C water bath to 1/3 of the original volume.
4. A method of preparation according to claim 3, characterized in that: the first time of the strong fire decoction is 60-70 min.
5. A method of preparation according to claim 3, characterized in that: the mixing mass ratio of the dregs to the water is 1: (8-12), and the time of the second slow fire decoction is 40-50 min.
6. A method of preparation according to claim 3, characterized in that: the mixing mass ratio of the secondary medicine residues to the water is 1: (3-7), wherein the time of the third slow fire decoction is 20-30 min.
7. Use of a Chinese medicinal composition according to claim 1 or 2 for the preparation of a medicament for the treatment of a fibrillation disorder.
8. A medicament for treating a fibrillation disorder, comprising: the raw materials comprise the traditional Chinese medicine composition as claimed in claim 1 or 2.
9. A medicament according to claim 8, characterized in that: the medicine also comprises pharmaceutically acceptable auxiliary materials.
10. A medicament according to claim 8, characterized in that: the dosage forms of the medicine comprise powder, pill, granule, paste or tablet.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311205581.8A CN117045754A (en) | 2023-09-19 | 2023-09-19 | Traditional Chinese medicine composition for treating fibrillation symptoms and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311205581.8A CN117045754A (en) | 2023-09-19 | 2023-09-19 | Traditional Chinese medicine composition for treating fibrillation symptoms and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117045754A true CN117045754A (en) | 2023-11-14 |
Family
ID=88659176
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311205581.8A Pending CN117045754A (en) | 2023-09-19 | 2023-09-19 | Traditional Chinese medicine composition for treating fibrillation symptoms and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117045754A (en) |
-
2023
- 2023-09-19 CN CN202311205581.8A patent/CN117045754A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111658701A (en) | Spleen-tonifying traditional Chinese medicine composition and application thereof | |
| US20030211178A1 (en) | Herbal composition for treatment of neuronal injuries and neuronal degeneration, methods to prepare the same and uses thereof | |
| CN112190638A (en) | Traditional Chinese medicine composition for treating insomnia after stroke in cerebral infarction recovery period and application thereof | |
| CN105031212A (en) | Drug for treating parkinson disease | |
| CN1273156C (en) | Oral Chinese medicinal preparation for treating vascular dementia | |
| CN115054649B (en) | A Chinese medicinal composition for treating diabetic peripheral neuropathy, and its preparation method | |
| CN110538220A (en) | Collateral-dredging bath formula for preventing and treating oxaliplatin peripheral neurotoxicity | |
| CN101361821A (en) | Medicine combination for treating diabetic peripheral neuropathy and preparation method thereof | |
| CN113827652B (en) | Traditional Chinese medicine composition for treating migraine as well as preparation method and application thereof | |
| CN106492105B (en) | Traditional Chinese medicine for treating wind-phlegm upward disturbance type dizziness | |
| CN117045754A (en) | Traditional Chinese medicine composition for treating fibrillation symptoms and preparation method and application thereof | |
| CN102872313B (en) | Traditional Chinese medicine qi-tonifying and kidney-nourishing decoction for treating henoch-schonlein purpura nephritis | |
| CN115252691A (en) | Traditional Chinese medicine composition for treating qi stagnation and blood stasis type coronary heart disease angina | |
| CN112741887B (en) | Traditional Chinese medicine composition for treating depression | |
| CN106214770B (en) | Application of collateral activating and pain relieving capsule in preparation of medicine for treating diabetic peripheral neuropathy | |
| CN109999155B (en) | Traditional Chinese medicine composition for treating Alzheimer disease and preparation method thereof | |
| Siddiqui et al. | The effects of new polyherbal Unani formulation AJMAL06 on serum creatinine level in chronic renal failure | |
| CN116270922B (en) | Prescription for eliminating turbid pathogen, resolving masses and removing arthralgia and application thereof | |
| CN108686094A (en) | A kind of Traditional Chinese medicine for decreasing blood sugar and preparation method thereof | |
| CN115737778B (en) | Traditional Chinese medicine preparation with pressure regulating effect | |
| CN104606596B (en) | A kind of Chinese patent drug for treating behcet disease and preparation method thereof | |
| CN114588242B (en) | Pharmaceutical composition for treating rheumatoid arthritis | |
| CN116036212B (en) | Traditional Chinese medicine for treating acute stage of ischemic stroke | |
| Zhang et al. | Staged Treatment for Anti-NMDA Receptor Encephalitis Based on Combined Western and Traditional Chinese Medicine | |
| CN111494560A (en) | Compound preparation for treating liver wind internal stirring type migraine and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |